Edgar Lomax Company’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$15.2M Buy
70,108
+49,260
+236% +$10.9M 1.09% 39
2025
Q4
$4.76M Sell
20,848
-505
-2% -$115K 0.36% 51
2025
Q3
$4.94M Sell
21,353
-6,265
-23% -$1.28M 0.39% 44
2025
Q2
$5.13M Sell
27,618
-450
-2% -$83.6K 0.32% 46
2025
Q1
$5.88M Sell
28,068
-36,505
-57% -$7.1M 0.37% 44
2024
Q4
$11.5M Sell
64,573
-1,280
-2% -$235K 0.74% 44
2024
Q3
$13M Sell
65,853
-1,025
-2% -$191K 0.79% 43
2024
Q2
$11.5M Sell
66,878
-820
-1% -$136K 0.74% 45
2024
Q1
$12.3M Buy
67,698
+16,194
+31% +$2.79M 0.76% 45
2023
Q4
$7.98M Sell
51,504
-2,050
-4% -$299K 0.52% 44
2023
Q3
$7.98M Sell
53,554
-975
-2% -$143K 0.54% 42
2023
Q2
$7.35M Sell
54,529
-739
-1% -$108K 0.48% 46
2023
Q1
$8.81M Sell
55,268
-14,210
-20% -$2.17M 0.57% 45
2022
Q4
$11.2M Sell
69,478
-370
-0.5% -$56.7K 0.68% 43
2022
Q3
$9.37M Sell
69,848
-400
-0.6% -$57.4K 0.65% 44
2022
Q2
$10.8M Buy
70,248
+1,980
+3% +$303K 0.67% 42
2022
Q1
$11.1M Sell
68,268
-209,085
-75% -$30.4M 0.65% 43
2021
Q4
$37.6M Sell
277,353
-2,775
-1% -$328K 2.25% 17
2021
Q3
$30.2M Sell
280,128
-3,530
-1% -$403K 1.94% 22
2021
Q2
$32M Sell
283,658
-6,775
-2% -$763K 1.99% 20
2021
Q1
$31.4M Buy
290,433
+166,690
+135% +$17.8M 1.96% 21
2020
Q4
$13.3M Sell
123,743
-2,200
-2% -$211K 0.9% 35
2020
Q3
$11M Buy
125,943
+5,100
+4% +$480K 0.85% 38
2020
Q2
$11.9M Buy
120,843
+2,500
+2% +$220K 0.95% 35
2020
Q1
$9.02M Sell
118,343
-182,400
-61% -$15.5M 0.8% 38
2019
Q4
$26.6M Sell
300,743
-7,500
-2% -$623K 1.72% 24
2019
Q3
$23.3M Sell
308,243
-3,300
-1% -$226K 1.56% 24
2019
Q2
$22.7M Sell
311,543
-4,700
-1% -$369K 1.54% 24
2019
Q1
$25.5M Buy
316,243
+110,775
+54% +$9.06M 1.75% 22
2018
Q4
$18.9M Sell
205,468
-3,000
-1% -$264K 1.44% 23
2018
Q3
$19.7M Sell
208,468
-7,500
-3% -$711K 1.32% 25
2018
Q2
$20M Buy
215,968
+1,525
+0.7% +$149K 1.41% 25
2018
Q1
$20.3M Buy
214,443
+85,125
+66% +$9.35M 1.46% 26
2017
Q4
$12.5M Sell
129,318
-4,015
-3% -$378K 0.85% 38
2017
Q3
$11.8M Sell
133,333
-11,778
-8% -$897K 0.84% 38
2017
Q2
$10.5M Sell
145,111
-4,000
-3% -$269K 0.72% 42
2017
Q1
$9.72M Buy
149,111
+31,330
+27% +$1.97M 0.65% 45
2016
Q4
$7.38M Sell
117,781
-9,996
-8% -$610K 0.47% 50
2016
Q3
$8.06M Buy
127,777
+30
+0% +$1.94K 0.5% 46
2016
Q2
$7.91M Buy
127,747
+6,187
+5% +$377K 0.5% 48
2016
Q1
$6.94M Buy
121,560
+4,500
+4% +$251K 0.48% 49
2015
Q4
$6.93M Sell
117,060
-4,450
-4% -$256K 0.51% 48
2015
Q3
$6.61M Sell
121,510
-4,200
-3% -$273K 0.5% 46
2015
Q2
$8.45M Sell
125,710
-1,575
-1% -$103K 0.57% 40
2015
Q1
$7.45M Sell
127,285
-11,900
-9% -$719K 0.49% 47
2014
Q4
$9.11M Sell
139,185
-206,990
-60% -$13M 0.57% 40
2014
Q3
$20M Buy
346,175
+8,650
+3% +$480K 1.36% 29
2014
Q2
$19.1M Buy
337,525
+600
+0.2% +$31.5K 1.35% 26
2014
Q1
$17.3M Buy
336,925
+120,550
+56% +$6.09M 1.28% 29
2013
Q4
$11.4M Buy
216,375
+59,000
+37% +$2.9M 0.86% 38
2013
Q3
$7.04M Sell
157,375
-14,250
-8% -$632K 0.58% 49
2013
Q2
$7.09M Buy
+171,625
New +$7.51M 0.55% 49

Other funds holding ABBV

Edgar Lomax Company's ABBV Position: Q1 2026 in Review

Edgar Lomax Company increased its AbbVie (ABBV) stake by 236% in Q1 2026, buying an estimated $10.9M and bringing the position to 70,108 shares worth $15.2M. The position accounts for 1.09% of the portfolio, ranked #39.

Edgar Lomax Company first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $37.6M in Q4 2021. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Edgar Lomax Company held 70,108 shares of AbbVie worth $15.2M as of Q1 2026.
  • Edgar Lomax Company bought 49,260 AbbVie shares in Q1 2026, an estimated $10.9M.
  • AbbVie made up 1.09% of Edgar Lomax Company's portfolio in Q1 2026, its #39 holding.
  • Edgar Lomax Company first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Edgar Lomax Company's AbbVie position peaked at $37.6M in Q4 2021.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Edgar Lomax Company's 13F filing for Q1 2026, filed 12 May 2026.